17βE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFκB-dependent pathway

Hui Zhang, Xingbo Ζhao, Xingbo Zhao, Shu Liu, Jijun Li, Zeqing Wen, Mingjiang Li
Molecular and cellular endocrinology · 2009 · vol. 317(1-2) , pp. 31–43 · doi:10.1016/j.mce.2009.11.009 · PMID:19932734 · W2017190024
article OA: closed CC0 ⤵ 57 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

17β estradiol (E2) accelerates endometriosis cell growth by reducing PTEN expression, a process mediated by the NFκB signaling pathway.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Endometriosis Estradiol NF-kappa B PTEN Phosphohydrolase Signal Transduction Adult Cell Nucleus Cell Nucleus Cell Nucleus Cell Proliferation Cell Proliferation DNA DNA Endometriosis Enzyme Activation Enzyme Activation Epithelial Cells Epithelial Cells Epithelial Cells

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (57)

Cited by (50)

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:13:53.633898+00:00
unpaywall
last seen: 2026-06-13T17:26:54.343160+00:00
License: CC0 · commercial use OK